EMERGENT BIOSOLUTIONS INC (EBS)

US29089Q1058 - Common Stock

2.29  +0.13 (+6.02%)

After market: 2.29 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EMERGENT BIOSOLUTIONS INC

NYSE:EBS (4/23/2024, 7:04:00 PM)

After market: 2.29 0 (0%)

2.29

+0.13 (+6.02%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap119.97M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EBS Daily chart

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,500 full-time employees. The company went IPO on 2006-11-15. Its segments include Products Segment and Services Segment. The Products Segment includes the government-medical countermeasures (MCM) business, which focuses on procurement of MCM products and procured product candidates by domestic and international government customers. The company sells MCM products and procures product candidates to domestic and international non-government organizations and to governments outside of the United States. The company also includes the commercial business, which focuses on sales of NARCAN (naloxone HCI) Nasal Spray and its travelers' vaccines. The Services Segment consists of contract development and manufacturing (CDMO) services, which includes development services (process and analytical development), drug substance manufacturing and drug product manufacturing (fill/finish).

Company Info

EMERGENT BIOSOLUTIONS INC

400 Professional Dr, Suite 400

Gaithersburg MARYLAND 20879

P: 12406313200

CEO: Robert G. Kramer

Employees: 2500

Website: https://emergentbiosolutions.com/

EBS News

News Image2 days ago - Emergent BioSolutionsEmergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
News Image2 days ago - Emergent BioSolutionsEmergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at...

News Image20 days ago - Market News VideoCommit To Purchase Emergent BioSolutions At $2, Earn 37.8% Annualized Using Options
News Image23 days ago - Aquestive Therapeutics, Inc.Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors

News Imagea month ago - Emergent BioSolutionsEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
News Imagea month ago - Emergent BioSolutionsEmergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with...

EBS Twits

Here you can normally see the latest stock twits on EBS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example